After about three years, those who had received the two treatments had a 49% lower risk of cancer recurrence or death, and a 62% lower risk of their cancer spreading, compared to people who got only pembrolizumab.
Overall, 75% of the patients taking the two therapies survived with no recurrences at 2.5 years, compared to 56% of those on pembrolizumab.
Each of the treated patients received a custom-made vaccine tailored to the specific mutations in their tumor, showing significant and durable responses.
The results give us an extremely high degree of confidence that this effect is real and very long lasting.
[
add
]
[
|
|
...
]